Amova Asset Management Americas Inc. cut its holdings in shares of 10x Genomics (NASDAQ:TXG – Free Report) by 7.0% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,104,178 shares of the company’s stock after selling 381,975 shares during the period. 10x Genomics comprises about 1.5% of Amova Asset Management Americas Inc.’s portfolio, making the stock its 18th biggest position. Amova Asset Management Americas Inc. owned about 4.00% of 10x Genomics worth $108,311,000 at the end of the most recent quarter.
Several other hedge funds have also made changes to their positions in the business. Geneos Wealth Management Inc. acquired a new position in shares of 10x Genomics in the fourth quarter valued at approximately $38,000. Larson Financial Group LLC boosted its position in 10x Genomics by 164.4% in the 4th quarter. Larson Financial Group LLC now owns 2,364 shares of the company’s stock valued at $39,000 after buying an additional 1,470 shares during the period. Fifth Third Bancorp acquired a new position in shares of 10x Genomics in the first quarter worth $50,000. Van ECK Associates Corp grew its stake in shares of 10x Genomics by 85.9% in the fourth quarter. Van ECK Associates Corp now owns 3,668 shares of the company’s stock worth $60,000 after acquiring an additional 1,695 shares in the last quarter. Finally, EverSource Wealth Advisors LLC increased its position in shares of 10x Genomics by 203.9% during the second quarter. EverSource Wealth Advisors LLC now owns 7,490 shares of the company’s stock worth $87,000 after acquiring an additional 5,025 shares during the period. Institutional investors and hedge funds own 84.68% of the company’s stock.
Wall Street Analysts Forecast Growth TXG has been the subject of a number of recent research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of 10x Genomics in a report on Wednesday, June 24th. Canaccord Genuity Group increased their price target on 10x Genomics from $32.00 to $50.00 and gave the company a “buy” rating in a research report on Tuesday, July 14th. Bank of America boosted their price objective on 10x Genomics from $21.00 to $30.00 and gave the stock a “neutral” rating in a research report on Monday, April 20th. Leerink Partners upped their target price on shares of 10x Genomics from $23.00 to $40.00 and gave the stock a “market perform” rating in a research note on Friday. Finally, Morgan Stanley raised their target price on shares of 10x Genomics from $22.00 to $37.00 and gave the company an “equal weight” rating in a report on Thursday, July 9th. Four equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, 10x Genomics has a consensus rating of “Hold” and an average price target of $32.08.
Check Out Our Latest Stock Analysis on 10x Genomics
Insider Activity at 10x Genomics In other 10x Genomics news, CEO Serge Saxonov sold 30,000 shares of the company’s stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $34.44, for a total value of $1,033,200.00. Following the completion of the transaction, the chief executive officer owned 1,108,380 shares in the company, valued at $38,172,607.20. This represents a 2.64% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Shehnaaz Suliman sold 5,723 shares of the firm’s stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $32.63, for a total value of $186,741.49. Following the transaction, the director directly owned 31,722 shares in the company, valued at approximately $1,035,088.86. The trade was a 15.28% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 91,309 shares of company stock valued at $2,581,357 in the last ninety days. 8.84% of the stock is currently owned by insiders.
10x Genomics Stock Down 1.2% Shares of 10x Genomics stock opened at $43.22 on Tuesday. 10x Genomics has a 52 week low of $11.16 and a 52 week high of $46.32. The firm’s 50 day moving average is $32.61 and its two-hundred day moving average is $24.90. The firm has a market capitalization of $5.49 billion, a P/E ratio of -254.24 and a beta of 2.05.
10x Genomics (NASDAQ:TXG – Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.19. The business had revenue of $150.84 million during the quarter, compared to the consensus estimate of $146.41 million. 10x Genomics had a negative net margin of 3.55% and a negative return on equity of 2.86%. The company’s revenue was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.28) EPS. As a group, research analysts expect that 10x Genomics will post -0.79 earnings per share for the current fiscal year.
10x Genomics Company Profile (Free Report)
10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.
Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.
Recommended Stories Five stocks we like better than 10x Genomics The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story
Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINECRISPR Therapeutics AG $CRSP Shares Sold by Amova Asset Management Americas Inc.
NEXT HEADLINE »Tempus AI, Inc. $TEM Stake Boosted by Amova Asset Management Americas Inc.
Mitesco (OTCMKTS:MITI – Get Free Report) and 10x Genomics (NASDAQ:TXG – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.
Profitability This table compares Mitesco and 10x Genomics’ net margins, return on equity and return on assets.
Net Margins Return on Equity Return on Assets Mitesco N/A -2.18% -2,982.65% 10x Genomics -3.55% -2.86% -2.23% Analyst Recommendations This is a summary of recent ratings and target prices for Mitesco and 10x Genomics, as reported by MarketBeat.
Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mitesco 0 0 0 0 0.00 10x Genomics 1 10 4 0 2.20 10x Genomics has a consensus target price of $30.42, suggesting a potential downside of 31.62%. Given 10x Genomics’ stronger consensus rating and higher probable upside, analysts plainly believe 10x Genomics is more favorable than Mitesco.
Institutional and Insider Ownership 0.0% of Mitesco shares are owned by institutional investors. Comparatively, 84.7% of 10x Genomics shares are owned by institutional investors. 4.9% of Mitesco shares are owned by company insiders. Comparatively, 8.8% of 10x Genomics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Valuation & Earnings This table compares Mitesco and 10x Genomics”s top-line revenue, earnings per share and valuation.
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mitesco $40,000.00 54.20 $500,000.00 ($0.33) -0.25 10x Genomics $642.82 million 8.79 -$43.54 million ($0.17) -261.65 Mitesco has higher earnings, but lower revenue than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Mitesco, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk Mitesco has a beta of 4.95, suggesting that its share price is 395% more volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 2.05, suggesting that its share price is 105% more volatile than the S&P 500.
Summary 10x Genomics beats Mitesco on 8 of the 14 factors compared between the two stocks.
About Mitesco (Get Free Report)
Mitesco, Inc. does not have significant operations. Previously, it was engaged in healthcare technology and services business. Mitesco, Inc. is based in Vero Beach, Florida.
About 10x Genomics (Get Free Report)
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Receive News & Ratings for Mitesco Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mitesco and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEGalera Therapeutics (NASDAQ:GRTX) vs. Eagle Pharmaceuticals (NASDAQ:EGRX) Head to Head Review
, /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, announced it will report financial results for the second quarter ended June 30, 2026 after market close on Thursday, August 6, 2026. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call.
Interested parties may access a live webcast of the fireside chat on the "Investors" section of the company's website at: https://investors.10xgenomics.com/. The webcast will be archived and available for replay for at least 45 days after the event.
About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X, Facebook, Bluesky or YouTube.
Disclosure Information
10x Genomics uses filings with the Securities and Exchange Commission, its website (https://www.10xgenomics.com/), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
Key Takeaways 10x Genomics is collaborating with the Cleveland Clinic on bladder cancer diagnostic applications.The study will use Flex Apex and Xenium to find biomarkers tied to treatment response.The partnership could expand 10x Genomics' role in precision oncology and diagnostics. 10x Genomics (TXG - Free Report) recently entered into a multi-year research collaboration with the Cleveland Clinic to advance novel diagnostic applications for bladder cancer. The study will use the company's Flex Apex and Xenium platforms, with potential expansion to Atera, to identify biomarkers that may predict patient response to antibody-drug conjugates and immunotherapies.
From an investor's perspective, the collaboration marks another step in 10x Genomics' strategy to expand its technologies into clinical and diagnostic applications. The partnership could strengthen the company's position in precision oncology, broaden the use cases for its single-cell and spatial platforms and create long-term growth opportunities in cancer diagnostics.
Likely Trend of TXG Stock Following the NewsShares of TXG have traded flat since the announcement on Wednesday. In the year-to-date period, shares of the company surged 113.1% against the industry’s 20.1% decline. The S&P 500 increased 8.5% in the same time frame.
The collaboration with Cleveland Clinic is likely to strengthen 10x Genomics' long-term growth prospects by generating clinical evidence for the use of its single-cell and spatial technologies in precision oncology. Successful identification of predictive biomarkers could accelerate the adoption of Flex Apex, Xenium and Atera in translational research and future diagnostic applications, expand the company's presence in the high-growth oncology diagnostics market and create new revenue opportunities beyond its core research business.
TXG currently has a market capitalization of $4.08 billion.
Image Source: Zacks Investment Research
More on the NewsUnder the multi-year collaboration, 10x Genomics and the Cleveland Clinic are likely to initially analyze tumor samples from patients with advanced bladder cancer undergoing emerging therapeutic regimens. The study is likely to leverage TXG's Flex Apex and Xenium platforms and could later expand to the recently launched Atera platform. The partners aim to identify clinically relevant biomarkers that may predict patient responses to antibody-drug conjugates and immunotherapies, paving the way for future diagnostic development across multiple tumor types.
The research is likely to integrate single-cell transcriptomic profiling with spatial gene expression and protein measurements to generate a comprehensive view of tumor biology and the tumor microenvironment. Investigators are likely to assess tumor microenvironment composition, immune cell infiltration and the expression of therapeutic targets to better understand mechanisms underlying treatment response and resistance.
The collaboration is expected to generate a rich multimodal dataset linking molecular insights with clinical outcomes, supporting the development of next-generation precision oncology diagnostics and advancing the scientific understanding of bladder cancer.
Favorable Industry Prospect for TXGPer a report by Precedence Research, the global bladder cancer therapeutics diagnostics market size accounted for $5.68 billion in 2025 and is predicted to increase from $6.01 billion in 2026 to approximately $10.04 billion by 2035, expanding at a CAGR of 5.86%.
The bladder cancer diagnostics market is expanding rapidly, driven by the rising prevalence and awareness of the disease, alongside advances in precision medicine, personalized treatment approaches and non-invasive diagnostic technologies.
A Recent Development by TXGRecently, 10x Genomics announced the acquisition of Proteintech Genomics, a division within Proteintech Group that develops high-plex proteomic solutions for single-cell and spatial biology applications. The move expands TXG's capabilities in proteomics and supports its broader strategy of advancing multiomics research through integrated RNA and protein analysis.
Proteintech Genomics brings technologies, including the Human Discovery Panel, an antibody-based single-cell protein panel compatible with 10x Genomics' Flex chemistry workflows.
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , West Pharmaceutical (WST - Free Report) and Intuitive Surgical (ISRG - Free Report) .
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a first-quarter 2026 adjusted earnings per share (EPS) of $1.12 per share, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
GMED has an estimated long-term earnings growth rate of 10.2% compared with the industry’s 12.6% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.
West Pharmaceutical, currently flaunting a Zacks Rank #1, reported first-quarter 2026 EPS of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%.
WST has an estimated long-term earnings growth rate of 13.9% compared with the industry’s 9.5% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.
Intuitive Surgical, carrying a Zacks Rank #2 at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.
ISRG has a long-term estimated growth rate of 14.6% compared with the industry’s 12.6% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Collaboration aims to identify biomarkers predictive of antibody-drug conjugate (ADC) treatment response using 10x's single cell and spatial platforms
, /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced a research collaboration with Cleveland Clinic, a nonprofit multispecialty academic medical center that integrates clinical care with research and education, to advance research in novel diagnostics for bladder cancer.
This collaboration is part of 10x's broader efforts to partner with leading research institutions to generate the evidence needed to support the future development of diagnostic applications across oncology and other disease areas.
Through this multi-year collaboration, the study intends to initially examine tumor samples from patients with advanced bladder cancer undergoing emerging therapeutic regimens using 10x's Flex Apex and Xenium platforms, with the goal of expanding to the recently announced Atera platform. The research aims to identify clinically relevant biomarkers that may help predict bladder cancer patient response to treatment and support future diagnostic development across tumor types.
Bladder cancer remains a complex and heterogeneous disease, with variable responses to therapies such as antibody-drug conjugates and immunotherapies. A major challenge in oncology is determining which therapies are most likely to benefit individual patients. By integrating single cell and spatial analysis, the research aims to generate a more comprehensive understanding of tumor biology and the tumor microenvironment, including features that may influence treatment response and resistance, which remain difficult to characterize using conventional approaches.
"We look forward to collaborating with 10x Genomics on this promising work. This collaboration has the potential to shed new light into the mechanisms underlying therapeutic response in a number of major cancer types," said Timothy Chan, MD, PhD, Chair, Department of Cancer Sciences, Cleveland Clinic.
The study is expected to include tumor samples from patients treated with antibody-drug conjugates and immunotherapy and to integrate single-cell transcriptomic profiling, spatial gene expression and protein measurements. Researchers plan to analyze tumor microenvironment composition, immune cell infiltration and expression of therapeutic targets to better understand mechanisms of response and resistance.
"One of the central challenges in oncology today is understanding why patients respond differently to the same therapy," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "There is a clear need for biomarkers that can guide treatment decisions, and we believe Flex Apex, Xenium and now Atera are uniquely suited to uncover them. These insights will be critical to enabling a new generation of diagnostic approaches in oncology."
The collaboration is expected to generate a comprehensive, multimodal dataset linking single cell and spatial insights with clinical outcomes, helping to advance the scientific understanding of treatment response in bladder cancer and support future diagnostic applications.
About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X, Facebook, Bluesky or YouTube.
Toronto, Ontario--(Newsfile Corp. - June 17, 2026) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) (OTCQX: TORXF) announces the results of its 2026 annual and special meeting of shareholders (the "Meeting") held virtually today.
The Meeting marked the retirement of Jody Kuzenko and the formal appointment of Andrew Snowden as President and CEO of the Company. Mr. Snowden was also elected to the Board of Directors along with the re-election of seven current Directors, as well as the re-appointment of Rick Howes as Chair of the Board.
Rick Howes, Chair of the Board of Torex, stated:
"On behalf of the Board of Directors and everyone at the Company, I want to extend my sincere appreciation to Jody for her exceptional leadership at Torex over the past eight years. Jody leaves the business in an excellent position for the next chapter of growth and success, and we wish her all the very best as she steps into her well-deserved retirement.
"The Board looks forward to working with Andrew in his new role as President and CEO as we continue to execute on our strategic pillars to build one of the best mining companies in the industry as a diversified, Americas-focused precious metals producer.
"Finally, to our shareholders, thank you for your ongoing trust and support. We are firmly committed to seizing the many opportunities ahead in order to continue to generate significant and lasting value for those who choose to invest in us."
ITEM 1. ELECTION OF DIRECTORS
At the Meeting, all director nominees listed in the Company's management information circular (the "Circular") dated May 6, 2026, were elected as directors of the Company. Detailed results of the vote by ballot are as follows:
DIRECTORVOTE TYPENUMBER OF VOTES% OF VOTESRichard A. HowesFor
Withheld73,557,809
69,57399.91%
0.09%Andrew SnowdenFor
Withheld73,616,975
10,40799.99%
0.01%Caroline DonallyFor
Withheld73,035,733
591,64999.20%
0.80%Jennifer J. HooperFor
Withheld73,209,711
417,67199.43%
0.57%Jay C. KellermanFor
Withheld72,793,419
833,96398.87%
1.13%Rosalie C. MooreFor
Withheld73,587,235
40,14799.95%
0.05%Rodrigo SandovalFor
Withheld72,915,027
712,35599.03%
0.97%Jacques PerronFor
Withheld73,587,700
39,68299.95%
0.05%ITEM 2. APPOINTMENT OF AUDITOR
On a vote by ballot, KPMG LLP, Chartered Professional Accountants, were re-appointed as auditors of the Company, and the directors were authorized to fix their remuneration.
VOTES FOR % VOTES FORVOTES WITHHELD% OF VOTES WITHHELD74,711,61898.74%955,6051.26%ITEM 3. APPROVAL OF NAME CHANGE
On a vote by ballot, a special resolution was passed authorizing and approving an amendment to the articles of the Company to change the name of the Company to "Torex Resources Inc.", or such other name as the Board of Directors of the Company, in its sole discretion, may approve, subject to regulatory approval. The Company expects to officially adopt the Company's new name later this year.
VOTES FOR % VOTES FORVOTES AGAINST% OF VOTES AGAINST75,467,15999.74%200,0650.26%ITEM 4. 'SAY ON PAY' EXECUTIVE COMPENSATION
On a vote by ballot, a non-binding advisory resolution was passed accepting the approach to executive compensation disclosed in the Circular and delivered in advance of the Meeting.
VOTES FOR % VOTES FORVOTES AGAINST% OF VOTES AGAINST71,129,95696.61%2,497,4263.39%The formal report on voting results with respect to all matters voted upon at the Meeting will be filed on SEDAR+ at http://www.sedarplus.ca/.
ABOUT TOREX GOLD RESOURCES INC.
Torex Gold Resources Inc. is a Canadian mining company engaged in the exploration, development, and production of gold, copper, and silver from its flagship Morelos Complex in Guerrero, Mexico. The Company also owns the Los Reyes gold-silver project in Sinaloa and a portfolio of early-stage exploration properties, including the Batopilas and Guigui projects in Chihuahua, Mexico, and the Medicine Springs project in Nevada, USA as well as an option to acquire the Gryphon project in Nevada, USA.
The Company's key strategic objectives are: optimize Morelos production and costs; disciplined growth and capital allocation; grow reserves and resources; project delivery excellence; retain and attract best industry talent; and be an industry leader in responsible mining. In addition to realizing the full potential of the Morelos Property, the Company continues to seek opportunities to acquire assets that enable diversification and deliver value to shareholders.
CAUTIONARY NOTES ON FORWARD-LOOKING STATEMENTS
This press release contains "forward-looking statements" and "forward-looking information" within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements regarding the change of the Company's name; and the Company's key strategic objectives: optimize Morelos production and costs; disciplined growth and capital allocation; grow reserves and resources; project delivery excellence; retain and attract best industry talent; and be an industry leader in responsible mining. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "continue", "strategy" and "ongoing" or variations of such words. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking information, including, without limitation, those risk factors identified in the Company's annual information form ("AIF") and management's discussion and analysis ("MD&A"). Forward-looking information is based on the assumptions discussed in the AIF and MD&A and such other reasonable assumptions, estimates, analysis and opinions of management made in light of its experience and perception of trends, current conditions and expected developments, and other factors that management believes are relevant and reasonable in the circumstances at the date such statements are made. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in the forward-looking information, there may be other factors that cause results not to be as anticipated. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information, whether as a result of new information or future events or otherwise, except as may be required by applicable securities laws.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/301919
Source: Torex Gold Resources Inc.
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
, /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced it will report financial results for the first quarter ended March 31, 2026 after market close on Thursday, May 7, 2026. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call.
Interested parties may access a live webcast of the fireside chat on the "Investors" section of the company's website at: https://investors.10xgenomics.com/. The webcast will be archived and available for replay for at least 45 days after the event.
About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X, Facebook, Bluesky or YouTube.
Disclosure Information
10x Genomics uses filings with the Securities and Exchange Commission, its website (https://www.10xgenomics.com/), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
Hinge Health (NYSE:HNGE – Get Free Report) and 10x Genomics (NASDAQ:TXG – Get Free Report) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, earnings, valuation, dividends and analyst recommendations.
Profitability This table compares Hinge Health and 10x Genomics’ net margins, return on equity and return on assets.
Net Margins Return on Equity Return on Assets Hinge Health N/A N/A N/A 10x Genomics -6.77% -6.89% -5.34% Analyst Ratings This is a breakdown of recent ratings and target prices for Hinge Health and 10x Genomics, as provided by MarketBeat.com.
Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hinge Health 1 1 16 1 2.89 10x Genomics 2 10 5 0 2.18 Hinge Health currently has a consensus price target of $56.73, indicating a potential upside of 36.71%. 10x Genomics has a consensus price target of $19.46, indicating a potential downside of 23.22%. Given Hinge Health’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Hinge Health is more favorable than 10x Genomics.
Earnings & Valuation This table compares Hinge Health and 10x Genomics”s revenue, earnings per share and valuation.
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hinge Health $587.86 million 5.56 -$528.26 million ($12.81) -3.24 10x Genomics $642.82 million 5.04 -$43.54 million ($0.35) -72.43 10x Genomics has higher revenue and earnings than Hinge Health. 10x Genomics is trading at a lower price-to-earnings ratio than Hinge Health, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership 84.7% of 10x Genomics shares are owned by institutional investors. 9.4% of 10x Genomics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary Hinge Health beats 10x Genomics on 9 of the 14 factors compared between the two stocks.
About Hinge Health (Get Free Report)
Our vision is to build a new health system that transforms outcomes, experience and costs by using technology to scale and automate the delivery of care. Hinge Health leverages software, including AI, to largely automate care for joint and muscle health, delivering an outstanding member experience, improved member outcomes, and cost reductions for our clients. We have designed our platform to address a broad spectrum of MSK care—from acute injury, to chronic pain, to post-surgical rehabilitation. Members receive personalized and largely automated MSK care through our AI-powered motion tracking technology and a proprietary electrical nerve stimulation wearable device, all designed and monitored by our AI-supported care team of licensed physical therapists, physicians, and board-certified health coaches. Our platform can improve pain and function and reduce the need for surgeries, all while driving health equity by allowing members to engage in their exercise therapy sessions from anywhere and embrace movement as a way of life. There is no shortage of new technologies in the healthcare industry, yet the cost of care continues to rise. In other industries, the launch of new technologies has generally improved end-user experiences and lowered costs. In healthcare, however, new technologies have not always been successful in lowering the cost of care or improving clinical outcomes. We believe there are two key reasons for healthcare’s idiosyncratic response to technology: • Automating most aspects of care is difficult because so many healthcare interventions involve unstructured physical tasks. • The current framework for healthcare reimbursement has specific pathways to pay for care, which means new technologies are constrained to deliver within this framework. At Hinge Health, we have taken these challenges head-on. To address the automation of care, we have weaved together AI-enabled capabilities – such as our AI-powered motion tracking technology, TrueMotion, our proprietary FDA-cleared wearable device, Enso, and our AI-supported care team – to deliver scalable and personalized MSK care. According to our estimates based on data from 2024, our platform reduced the number of human care team hours associated with traditional physical therapy by approximately 95%. We have done this while improving our high member satisfaction over time. To address healthcare reimbursement constraints, we developed novel billing methods for our innovative technology by both directly selling to employers while also partnering with health plans, pharmacy benefit managers (“PBMs”), third-party administrators (“TPAs”), and other ecosystem entities to efficiently provide our platform to clients and members. While the MSK market is massive, existing solutions have fallen short as they are often expensive, ineffective, inconvenient to access, and delivered in a one-to-one or few-to-one care setting. Effective MSK care should be engaging, easy to use, and accessible anytime, anywhere. We developed Hinge Health to be simple and accessible, complete, personalized, and scalable. • Simple and accessible: We provide members access to our platform at no direct cost to them and without a copay or deductible. Members can access our broad spectrum of MSK care through a single on-demand app, designed to provide an engaging, seamless, and convenient digital experience whenever and wherever the member chooses. Potential members can complete a simple intake form, download the app, and start exercises soon thereafter. During the year ended December 31, 2024, approximately 64% of members were onboarded on the same day they completed their intake form, and approximately 75% of members were onboarded within the first week. • Complete: Our platform offers a wide range of support with multiple programs across many affected areas to provide a continuum of care from prevention to treatment of acute injury and chronic pain, as well as surgery decision support and post-surgical recovery. We also offer non-addictive and non-invasive pain relief via electrostimulation through our proprietary FDA-cleared wearable device, Enso, that is seamlessly integrated into our platform. • Personalized: Our platform delivers smarter care through AI and machine learning. Our AI model is trained on a large, proprietary MSK data set, and our technology is continuously learning and improving as each new member enrolls and engages with our programs, which creates a positive feedback loop. As of March 31, 2025, we had treated over one million members and our programs had tracked over 74 million activity sessions and 32 million member-reported outcome logs. We focus on personalization to keep members moving: from customized care plans to real-time in-app exercise feedback based on the member’s input and our proprietary motion tracking technology. • Scalable: Our AI-powered motion tracking technology, TrueMotion, allows us to deliver scalable and largely automated care. According to our estimates based on data from 2024, our platform reduced the number of human care team hours associated with traditional physical therapy by approximately 95%. While most of our programs provide members with access to a dedicated care team, our technology automates most aspects of care delivery while allowing our members to progress through their exercise therapy sessions on their own time. We have developed an efficient go-to-market model by working directly with our partners and clients. We seek to be the best solution on the market, the most validated solution on the market, and the easiest to buy. Our clients are primarily self-insured employers and include many of the nation’s leading enterprises across a broad range of industries and sizes. Within this segment, we also serve many public sector self-insured employers, such as state and local city governments and labor unions. In most instances, we partner with clients’ health plans, TPAs, PBMs, or other ecosystem entities to reduce the friction of contracting, procurement, security and IT reviews, onboarding, and billing. We are also in the early stages of expanding to serve health plans’ fully-insured and Medicare Advantage populations and federal insurance plans. As of December 31, 2024, we had approximately 20 million contracted lives across more than 2,250 clients. We had active client agreements with 49% of the Fortune 100 companies and 42% of the Fortune 500 companies, as of December 31, 2024. Despite this progress, our current contracted lives only represent 5% of our total addressable market. We believe that we grow efficiently because of our scalable, repeatable go-to-market model. We sell through our direct sales force and our partners. Once we contract with a client, we are most often the sole digital MSK care provider offered to their contracted lives. Our average contract term is three years. For the term of each contract, we are able to enroll, engage, and re-engage the client’s eligible lives, driving a recurring, repeatable revenue model, which is demonstrated in our net dollar retention of 117% as of December 31, 2024. Our 12-month client retention rate was 98% as of December 31, 2024. Additionally, we have a high level of client satisfaction, as shown by our client net promoter score (“NPS”) of 87 as of October 31, 2024. We also invested early in building our partner network. As of March 31, 2025, we had over 50 partners. Our partners include the five largest national health plans by self-insured lives, and the top three PBMs by market share. As of that date, we had retained 100% of our partners that we chose to work with since inception, excluding partners who were acquired. We have experienced significant growth since our inception, with a recurring revenue business model. As of December 31, 2024, we had over 532,000 members and more than 2,250 clients, compared to approximately 371,000 members and approximately 1,650 clients as of December 31, 2023. Our principal executive offices are located in San Francisco, California.
About 10x Genomics (Get Free Report)
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Receive News & Ratings for Hinge Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hinge Health and related companies with MarketBeat.com's FREE daily email newsletter.
Enables Whole-Transcriptome In Situ Spatial Biology with Single-Cell Sensitivity at Scale
Debuts at AACR Annual Meeting 2026 with Data from Leading Research Institutions, Including the June Lab at the Perelman School of Medicine, University of Pennsylvania and German Cancer Research Institute (DKFZ)
, /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced Atera, a new in situ spatial biology platform engineered to deliver whole-transcriptome spatial analysis with single-cell sensitivity at unprecedented scale.
Biology is best understood by measuring molecules and cells within intact tissue, where gene expression, cellular states and spatial organization together shape how disease emerges and evolves. Historically, these dimensions have been studied using separate tools, often at limited scale, precluding a complete view of how biological systems function. Spatial biology provides the path toward a comprehensive measurement of biology in its native context.
Until now, spatial technologies have been constrained by tradeoffs between scale, sensitivity and gene selection. Atera removes these limitations, enabling the complete measurement of biology, in its native context at single-cell resolution and at scale, without compromise. It marks a fundamental shift in how biology is analyzed and understood.
Atera is engineered to enable large-scale whole-transcriptome spatial studies across both fresh-frozen and FFPE tissue, supporting diverse applications in both discovery and translational research.
"At 10x, our mission is to accelerate the mastery of biology to advance human health," said Serge Saxonov, Chief Executive Officer and Co-founder of 10x Genomics. "Biology is inherently complex, and as much progress as we have made, we still understand only a fraction of how it works. Progress in medicine depends on confronting that complexity directly, which requires measuring biology as it actually functions: systems of individual cells, expressing specific transcripts, in precise locations within tissue. Atera removes the trade-offs that have constrained research, unlocking a new era of insight that will transform our understanding of science and human health."
Carl June's Opening Plenary session at the American Association for Cancer Research (AACR) Annual Meeting 2026 will include data from the June Lab's early access samples analyzed on Atera.
"Spatial tools have always been important in understanding the tumor microenvironment. The samples we work with are rare, collected from glioblastoma patients treated with first-in-human bivalent CAR T cells, so it is critical to capture every layer of information possible," said Andrew Rech, Instructor of Pathology & Laboratory Medicine in the Carl June Lab at the Center for Cellular Immunotherapies at the University of Pennsylvania. "Using Atera has been extremely exciting for advancing our studies because its very high spatial resolution has allowed us to generate tumor microenvironment data from patients treated with CAR T cells, resolve rare immune cells, including T cells, in the post-treatment tumor microenvironment, and better understand tumor dynamics after treatment at a level that was not attainable in our prior lower-plex spatial work."
Data presented at AACR by the German Cancer Research Center (DKFZ) will highlight Atera's ability to challenge prevailing assumptions and uncover cancer biology not accessible with legacy approaches. Researchers distinguished multiple malignant and stem cell states, across disease stages, within a single colorectal tumor sample and mapped how these populations interact with the surrounding immune microenvironment. Notably, tumors previously characterized as having limited or low immune infiltration were found to harbor active and diverse immune cell populations, revealing a more complex immune landscape that could inform future therapeutic strategies and drug development.
Leading life sciences organizations and research institutions have already committed to utilizing Atera at scale, underscoring strong demand for high-throughput, high-sensitivity spatial analysis across both whole-transcriptome and targeted applications.
As the Human Cell Atlas (HCA) continues its mission to map every cell type in the human body, its success will require uncompromised spatial biology at scale, and Atera will enable the consortium to achieve its next set of ambitious goals.
"Whole-transcriptome spatial transcriptomics transforms tissues into living maps, enabling scientists to visualize complex cellular interactions in disease, uncover hidden mechanisms in clinical specimens and identify new therapeutic targets. Seeing this platform early made it clear that it represents a significant step forward for spatial biology. We expect Atera to fundamentally expand the scope of our translational research and accelerate target discovery in inflammatory and fibrotic diseases," said Kevin Wei, MD, PhD, Brigham and Women's Hospital.
Global service providers are moving to adopt Atera to support the next generation of spatial studies. Macrogen, a leading global Contract Research Organization (CRO), along with its U.S. subsidiary Psomagen, has committed to deploying multiple Atera instruments, becoming the first global service provider to adopt the platform. This investment reflects growing demand for high-throughput, uncompromised spatial analysis in biopharma and translational research, and positions Macrogen to support large-scale spatial programs.
Atera builds on the momentum and leadership in spatial biology established by Xenium, which remains the trusted solution for generating spatial data today. Bioptimus, a France-based AI biotech company, recently announced its partnership with 10x to build one of the world's largest spatial datasets, STELA, a global initiative to power their multimodal AI platform, M-Optimus. The data will provide the cornerstone of the AI-driven biology and drug discovery engine at Bioptimus. Bioptimus begins with Xenium to generate high-quality spatial data immediately, with plans to expand to Atera in 2027 as increased throughput enables the program to scale toward its full ambition.
"Atera reflects a first-principles approach to solving a core challenge in biology, which is how to measure complex systems without limitations," said Michael Schnall-Levin, Chief Technology Officer, Chief Strategy Officer and Founding Scientist at 10x Genomics. "We rethought the system from the ground up, optimizing each component across chemistry, hardware and software to enable what was previously impossible in spatial analysis. The result is a platform that delivers whole-transcriptome spatial data with single-cell sensitivity at scale. The Atera platform will substantially expand the scope of questions that can be addressed in spatial biology."
To harness the scale of insight generated by Atera's whole-transcriptome studies, 10x is introducing a powerful new cloud analysis platform to securely store, analyze, visualize and collaborate on spatial datasets. Building on the foundation of Xenium Explorer, the new platform brings intuitive visualization into the web and pairs it with GPU-accelerated analysis, empowering biologists to bridge the gap between raw data and insight in minutes instead of hours. Importantly, researchers maintain full control over their data and workflows with Atera routing results to 10x Cloud, customer-managed cloud or on-premise data storage.
Broad accessibility to Atera is critical to enabling biological impact. To ensure researchers can access the new platform, regardless of their project size or infrastructure, 10x has launched Catalyst Research Services, enabling direct submission of samples for whole-transcriptome spatial analysis. The program offers flexible access packages, with pre-booking now available and sample processing beginning alongside Atera's commercial availability.
10x Genomics at AACR 2026
Atera will be introduced at the AACR Annual Meeting 2026, where 10x will host in-person and digital launch events that include early data generated on the platform; additionally, the company will host an Exhibitor Spotlight Presentation on Atera.
Digital Launch Event: Register for the webinar here. Featured Presentations and Posters: Exhibitor Spotlight Presentation: 10x Genomics will introduce Atera, including a presentation from the German Cancer Research Center (DKFZ) with data generated on the platform, on April 19 at 1:30 PM PT in Spotlight Theater C, Sails Pavilion, San Diego Convention Center. Poster #7116: Atera enables clinical-scale spatial studies by overcoming limitations in cost, workflow and performance, generating high-resolution, low-noise datasets optimized for AI-driven biomarker discovery and early cancer detection. Poster #6216: Whole-transcriptome spatial analysis with Atera reveals TME remodeling genes and mitotic signaling at the tumor invasive front, providing new mechanistic insight into tumor progression and immune evasion in cervical and breast cancer. Pre-orders for Atera are now open. The platform is expected to begin shipping in the second half of 2026. 10x Genomics contemplated the launch of Atera when it provided its full-year 2026 financial outlook in February.
Additional details on the platform can be found in the Atera media kit.
About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X, Facebook, Bluesky or YouTube.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements included in this press release, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "see," "estimate," "predict," "potential," "would," "likely," "seek" or "continue" or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics' products and collaborations. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management. Actual outcomes and results could differ materially from these statements due to a number of factors and such statements should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release. 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in 10x Genomics' expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. The material risks and uncertainties that could affect 10x Genomics, Inc.'s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's most recently-filed 10-K for the fiscal year ended December 31, 2025 and elsewhere in the documents 10x Genomics, Inc. files with the Securities and Exchange Commission from time to time.
Disclosure Information
10x Genomics uses filings with the Securities and Exchange Commission, its website (https://www.10xgenomics.com/), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
Key Takeaways 10x Genomics unveiled Atera, a spatial biology platform for whole-transcriptome analysis at scale.Atera removes tradeoffs in scale, sensitivity and coverage, boosting appeal in research and drug discovery.Early adoption and partnerships signal demand, supporting TXG's growth in spatial biology markets. 10x Genomics (TXG - Free Report) recently unveiled Atera, a next-generation in situ spatial biology platform designed to deliver whole-transcriptome analysis with single-cell sensitivity at scale. Unveiled at the American Association for Cancer Research Annual Meeting 2026, the launch highlights TXG’s continued push to advance how researchers study complex biological systems within intact tissue environments.
The new platform aims to overcome long-standing tradeoffs in spatial biology, positioning TXG to tap into growing demand across translational research and drug discovery. Early adoption by leading research institutions and service providers signals strong interest, reinforcing the company’s innovation-driven growth narrative and long-term opportunity in high-throughput spatial analysis.
Likely Trend of TXG Stock Following the NewsShares of TXG have gained 3.3% since the announcement of the launch. In the year-to-date period, shares of the company gained 59.9% against the industry’s 19.1% decline. The S&P 500 increased 4.2% in the same time frame.
The Atera launch can meaningfully strengthen 10x Genomics’ long-term business by expanding its total addressable market and deepening its moat in spatial biology. By eliminating tradeoffs between scale, sensitivity and gene coverage, Atera positions TXG as a go-to platform for large-scale, high-resolution studies, attracting biopharma, academic and clinical customers. This should drive higher instrument placements, recurring consumables revenue and growing adoption of its cloud-based analysis ecosystem. Over time, stronger integration into drug discovery workflows and large consortium projects could enhance visibility, create sticky customer relationships and support durable revenue growth.
TXG currently has a market capitalization of $3.33 billion.
Image Source: Zacks Investment Research
More on the NewsFrom a technology and infrastructure standpoint, Atera reflects a ground-up redesign of spatial analysis, integrating advances across chemistry, hardware and software to remove longstanding limitations. To complement the platform, TXG is introducing a new cloud-based analysis solution that enables secure data storage, visualization and GPU-accelerated processing, significantly reducing time from raw data to insight.
Researchers can maintain full control over workflows through flexible deployment options, including cloud and on-premise environments. Additionally, the company has launched Catalyst Research Services, allowing customers to directly submit samples for analysis, with flexible access models aimed at broadening adoption as Atera moves into commercial availability.
The platform also builds on 10x Genomics existing spatial biology ecosystem, particularly its Xenium solution, while expanding into large-scale data-driven applications. Bioptimus, a France-based AI biotech company, has partnered with 10x Genomics to develop one of the world’s largest spatial datasets under the STELA initiative to power its M-Optimus platform. The program will initially utilize Xenium, with plans to transition to Atera in 2027 as throughput scales. Management emphasized that Atera’s integrated system design significantly expands the scope of biological questions that can be addressed, positioning it as a key enabler of next-generation research and AI-driven drug discovery.
Adoption momentum is already taking shape among global service providers. Macrogen, along with its U.S. subsidiary Psomagen, has committed to deploying multiple Atera systems, becoming the first global service provider to adopt the platform. This investment reflects increasing demand for high-throughput, uncompromised spatial analysis in biopharma and translational research, positioning Macrogen to support large-scale programs and reinforcing early commercial traction for Atera.
Favorable Industry Prospect for TXGPer a report by Custom Market Insights, the global spatial biology market size is estimated at $1.48 billion in 2026 and is anticipated to reach $7.24 billion by 2035, expanding at a CAGR of 19.2% from 2026 to 2035.
Growth in spatial biology is driven by the rising demand for single-cell and tissue-level insights to better understand complex diseases like cancer. Expanding use in drug discovery, precision medicine and AI-driven research, along with advances in high-throughput sequencing technologies, is accelerating market adoption.
A Recent Development by TXGIn February, 10x Genomics announced that the PharosAI consortium, comprising four leading UK institutions, will leverage its Xenium platform to build one of the world’s most comprehensive multimodal cancer datasets. It will be backed by 18.9 million Euros in UK government funding, along with support from charities and industry partners, to power AI-driven models aimed at enabling earlier diagnosis, precision therapies and faster drug discovery.
TXG’s Zacks Rank & Other Key PicksCurrently, TXG sports a Zacks Rank #1 (Strong Buy).
Some other top-ranked stocks from the broader medical space are Phibro Animal Health (PAHC - Free Report) , GE HealthCare Technologies (GEHC - Free Report) and Cardinal Health (CAH - Free Report) .
Phibro Animal Health, currently sporting a Zacks Rank #1, reported second-quarter fiscal 2026 adjusted earnings per share (EPS) of 87 cents, which surpassed the Zacks Consensus Estimate by 27.1%. Revenues of $373.9 million beat the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 20.1%.
GE HealthCare Technologies, currently carrying a Zacks Rank #2 (Buy), reported fourth-quarter 2025 adjusted EPS of $1.44, which surpassed the Zacks Consensus Estimate by 0.7%. Revenues of $5.7 billion beat the Zacks Consensus Estimate by 1.9%.
GEHC has an estimated long-term earnings growth rate of 9.1% compared with the industry’s 12% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 7.5%.
Cardinal Health, currently carrying a Zacks Rank #2, reported a second-quarter fiscal 2026 adjusted EPS of $2.63, which surpassed the Zacks Consensus Estimate by 10%. Revenues of $65.6 billion beat the Zacks Consensus Estimate by 0.9%.
CAH has an estimated long-term earnings growth rate of 15% compared with the industry’s 9.3% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 9.3%.
SAN CARLOS, Calif.--(BUSINESS WIRE)--LiquidCell Dx, a precision diagnostics company building a blood-based platform for tumor microenvironment profiling, today announced the appointment of Mirna Jarosz as Chief Executive Officer and Vincent A. Miller, MD, as Senior Strategic Advisor. The appointments add operating, commercialization and clinical leadership as the company advances its platform and prepares for the next stage of growth. Comprehensive genomic profiling changed oncology by making t.
, /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate in a fireside chat at the BofA Securities 2026 Healthcare Conference on Wednesday, May 13, at 5:00 p.m. Pacific Time.
Interested parties may access a live webcast of the fireside chat on the "Investors" section of the company's website at: https://investors.10xgenomics.com/. The webcast will be archived and available for replay for at least 30 days after the event.
About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X, Facebook, Bluesky or YouTube.
Disclosure Information
10x Genomics uses filings with the Securities and Exchange Commission, our website (www.10xgenomics.com), press releases, public conference calls, public webcasts and our social media accounts as means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD.
10x Genomics (TXG - Free Report) is expected to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended March 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.
The earnings report, which is expected to be released on May 7, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise.
Zacks Consensus EstimateThis life science technology company is expected to post quarterly loss of $0.27 per share in its upcoming report, which represents a year-over-year change of +25%.
Revenues are expected to be $145.65 million, down 6% from the year-ago quarter.
Estimate Revisions TrendThe consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.
Price, Consensus and EPS Surprise
Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for 10x Genomics?For 10x Genomics, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +33.34%.
On the other hand, the stock currently carries a Zacks Rank of #3.
So, this combination indicates that 10x Genomics will most likely beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that 10x Genomics would post a loss of$0.19 per share when it actually produced a loss of -$0.13, delivering a surprise of +31.58%.
Over the last four quarters, the company has beaten consensus EPS estimates four times.
Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
10x Genomics appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
, /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31, 2026.
Recent Updates
Revenue was $150.8 million for the first quarter of 2026, representing a 3% decrease over the corresponding period of 2025. Excluding $16.8 million related to one-time license and royalty revenue in the first quarter of 2025, revenue increased 9% over the corresponding period of 2025. Launched Atera, a new platform to redefine how biology is measured and understood. Atera was engineered to deliver spatial whole-transcriptome analysis with single-cell sensitivity at unprecedented scale. The Company expects to start shipping Atera in the second half of 2026. Announced a partnership with Bioptimus, a global AI biotech company, to launch STELA, a multinational spatial data generation initiative to create foundational datasets connecting underlying biology with disease outcomes. The initiative is starting this effort on our Xenium platform and plans to expand to Atera over time. Ended the first quarter of 2026 with cash and cash equivalents and marketable securities of $539.8 million, representing a $112.9 million increase from March 31, 2025. "We had a solid start to the year, with double-digit growth in Single Cell consumables reaction volumes and double-digit growth in Spatial consumables revenue," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "The biggest highlight is our recent launch of Atera, which represents the most significant product introduction in our history. We are extremely encouraged by the extraordinary early customer response."
First Quarter 2026 Financial Results
Revenue was $150.8 million for the first quarter of 2026, a 3% decrease from the corresponding period of 2025. Excluding $16.8 million related to a patent litigation settlement recognized in the first quarter of 2025, revenue increased 9% over the corresponding period of 2025.
Gross margin was 70% for the first quarter of 2026, as compared to 68% for the corresponding prior year period. The increase in gross margin was primarily due to lower warranty costs and lower inventory write-downs, partially offset by a decrease in license and royalty revenue reflecting a non-recurring royalty benefit recognized in the first quarter of 2025.
Operating expenses were $123.2 million for the first quarter of 2026, a 15% decrease from $144.8 million for the corresponding prior year period. The decrease was primarily driven by lower outside legal expenses and personnel expenses, partially offset by a non-recurring gain on settlement of $9.2 million recognized in the first quarter of 2025.
Operating loss was $17.0 million for the first quarter of 2026, as compared to operating loss of $39.3 million for the corresponding prior year period.
Net loss was $13.5 million for the first quarter of 2026, as compared to a net loss of $34.4 million for the corresponding prior year period.
Cash and cash equivalents and marketable securities were $539.8 million as of March 31, 2026.
2026 Financial Guidance
10x Genomics is maintaining its full year 2026 revenue guidance of $600 million to $625 million. Excluding the non-recurring license and royalty revenue related to patent litigation settlements in 2025, this represents 0% to 4% growth over full year 2025.
Webcast and Conference Call Information
10x Genomics will host a conference call to discuss the first quarter 2026 financial results, business developments and outlook after market close on Thursday, May 7, 2026 at 1:30 PM Pacific Time / 4:30 PM Eastern Time. A webcast of the conference call can be accessed at http://investors.10xgenomics.com. The webcast will be archived and available for replay at least 45 days after the event.
About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X, Facebook, Bluesky or YouTube.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements included in this press release, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "outlook," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "see," "estimate," "predict," "potential," "would," "likely," "seek" or "continue" or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics, Inc.'s products, services, business strategy, collaborations and opportunities and 10x Genomics, Inc.'s financial performance and results of operations, including expectations regarding revenue and guidance. These statements are based on management's current expectations, forecasts, beliefs, estimates, assumptions and information currently available to management. Actual outcomes and results could differ materially from these statements due to a number of factors and such statements should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release. 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in 10x Genomics' expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. The material risks and uncertainties that could affect 10x Genomics, Inc.'s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's most recently-filed 10-K for the fiscal year ended December 31, 2025 filed on February 12, 2026 and the company's quarterly report on Form 10-Q for the quarter ended March 31, 2026 to be filed with the U.S. Securities and Exchange Commission ("SEC"), and elsewhere in the documents 10x Genomics, Inc. files with the SEC from time to time.
Disclosure Information
10x Genomics uses filings with the Securities and Exchange Commission, its website (www.10xgenomics.com), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
Contacts
Investors: [email protected]
Media: [email protected]
10x Genomics, Inc.
Condensed Consolidated Statements of Operations
(Unaudited)
(In thousands, except share and per share data)
Three Months Ended
March 31,
2026
2025
Products and services revenue
$ 149,896
$ 137,823
License and royalty revenue
947
17,060
Revenue (1)
150,843
154,883
Cost of products and services revenue (2)
44,665
49,438
Gross profit
106,178
105,445
Operating expenses:
Research and development (2)
56,847
64,245
Selling, general and administrative (2)
66,377
89,728
Gain on settlement
—
(9,200)
Total operating expenses
123,224
144,773
Loss from operations
(17,046)
(39,328)
Other income (expense):
Interest income
5,014
3,686
Other income (expense), net
(815)
2,136
Total other income
4,199
5,822
Loss before provision for income taxes
(12,847)
(33,506)
Provision for income taxes
623
852
Net loss
$ (13,470)
$ (34,358)
Net loss per share, basic and diluted
$ (0.10)
$ (0.28)
Weighted-average shares used to compute net loss per share, basic and diluted
128,291,153
122,606,091
__________________________
(1)
The following table represents total revenue by source for the periods indicated (in thousands). Spatial includes the Company's Visium and Xenium products:
Three Months Ended
March 31,
2026
2025
Instruments
Single Cell
$ 5,223
$ 5,913
Spatial
6,039
8,902
Total instruments revenue
11,262
14,815
Consumables
Single Cell
88,894
84,109
Spatial
40,907
31,247
Total consumables revenue
129,801
115,356
Services
8,833
7,652
Products and services revenue
149,896
137,823
License and royalty revenue
947
17,060
Total revenue
$ 150,843
$ 154,883
(1)
The following table presents revenue by geography based on the location of the customer for the periods indicated (in thousands):
Three Months Ended
March 31,
2026
2025
Americas
United States*
$ 76,693
$ 86,818
Americas (excluding United States)
3,406
3,752
Total Americas
80,099
90,570
Europe, Middle East and Africa
36,852
31,895
Asia-Pacific
China
15,837
16,883
Asia-Pacific (excluding China)
18,055
15,535
Total Asia-Pacific
33,892
32,418
Total revenue
$ 150,843
$ 154,883
*
Includes license and royalty revenue.
(2)
Includes stock-based compensation expense as follows:
For the quarter ended March 2026, 10x Genomics (TXG - Free Report) reported revenue of $150.84 million, down 2.6% over the same period last year. EPS came in at -$0.10, compared to -$0.36 in the year-ago quarter.
The reported revenue represents a surprise of +3.57% over the Zacks Consensus Estimate of $145.65 million. With the consensus EPS estimate being -$0.29, the EPS surprise was +65.52%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how 10x Genomics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Revenues- Services: $8.83 million versus the four-analyst average estimate of $8.05 million. The reported number represents a year-over-year change of +15.4%.Revenues- Instruments: $11.26 million versus the three-analyst average estimate of $12.47 million. The reported number represents a year-over-year change of -24%.Revenues- Instruments- Single Cell: $5.22 million versus $4.55 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -11.7% change.Revenues- Consumables- Single Cell: $88.89 million versus $87.8 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +5.7% change.Revenues- Consumables- Spatial: $40.91 million versus the three-analyst average estimate of $36.76 million. The reported number represents a year-over-year change of +30.9%.Revenues- Consumables: $129.8 million versus the three-analyst average estimate of $124.56 million. The reported number represents a year-over-year change of +12.5%.Revenues- Instruments- Spatial: $6.04 million compared to the $7.96 million average estimate based on three analysts. The reported number represents a change of -32.2% year over year.View all Key Company Metrics for 10x Genomics here>>>
Shares of 10x Genomics have returned -1.2% over the past month versus the Zacks S&P 500 composite's +11.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
10x Genomics (TXG - Free Report) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.36 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +65.52%. A quarter ago, it was expected that this life science technology company would post a loss of $0.19 per share when it actually produced a loss of $0.13, delivering a surprise of +31.58%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
10x Genomics, which belongs to the Zacks Medical Info Systems industry, posted revenues of $150.84 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 3.57%. This compares to year-ago revenues of $154.88 million. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
10x Genomics shares have added about 39.4% since the beginning of the year versus the S&P 500's gain of 7.6%.
What's Next for 10x Genomics?While 10x Genomics has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for 10x Genomics was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.21 on $147.9 million in revenues for the coming quarter and -$0.82 on $611.56 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical Info Systems is currently in the bottom 32% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Lucid Diagnostics Inc. (LUCD - Free Report) , another stock in the broader Zacks Medical sector, has yet to report results for the quarter ended March 2026. The results are expected to be released on May 15.
This company is expected to post quarterly loss of $0.05 per share in its upcoming report, which represents a year-over-year change of +68.8%. The consensus EPS estimate for the quarter has been revised 14.3% higher over the last 30 days to the current level.
Lucid Diagnostics Inc.'s revenues are expected to be $1.4 million, up 68.7% from the year-ago quarter.
Key Takeaways TXG beat Q1 estimates with a narrower loss and revenue growth excluding prior-year one-time items.10x Genomics grew consumables revenue 12.5% and expanded gross margin by 220 basis points.TXG maintained 2026 revenue guidance of $600M-$625M and ended Q1 with no debt. 10x Genomics (TXG - Free Report) delivered a loss per share of 10 cents in first-quarter 2026, narrower than the year-earlier loss per share of 36 cents. The figure surpassed the Zacks Consensus Estimate by 65.5%.
TXG's RevenuesTXG registered revenues of $150.8 million in the first quarter of 2026, which decreased about 2.6% year over year. Excluding $16.8 million related to one-time license and royalty revenue in the first quarter of 2025, revenues increased 9% year over year. However, the figure surpassed the Zacks Consensus Estimate by 3.57%.
TXG’s Business Units in DetailThe company reports revenue under two primary segments: Products and Services and License and royalty revenue.
Products and Services revenue totaled $149.9 million, up approximately 8.8% year over year. Within this segment, Total instruments revenues totaled $11.3 million, down 23.9% year over year. In contrast, Total consumables revenues were $129.8 million, representing a 12.5% year-over-year increase.
Services revenue totaled $8.8 million, up 15.4% year over year.
Meanwhile, License and royalty revenue was $0.9 million compared with $17.1 million in the prior-year quarter, which included $16.8 million related to one-time license and royalty revenue.
TXG's Geographical DistributionGeographically, 10x Genomics derives revenues from three major regions: the Americas, Europe, the Middle East and Africa (EMEA), and Asia-Pacific.
In the first quarter of 2026, Total Americas’ revenues were $80.1 million, reflecting a 11.6% year-over-year decline.
EMEA revenues totaled $36.9 million, up approximately 15.5% year over year.
Meanwhile, Total Asia-Pacific revenues were $33.9 million, representing 4.4% year-over-year growth.
TXG's Margin TrendIn the quarter under review, TXG’s gross profit improved 0.7% year over year to $106.2 million. The gross margin expanded 220 basis points (bps) to 70.3%.
Selling, general and administrative expenses fell 26% year over year to $66.4 million. Research and development expenses declined 11.5% year over year to $56.8 million. Total operating expenses of $123.2 million decreased 14.9% year over year.
Total operating loss was $17 million, reflecting an improvement from the prior-year loss of $39.3 million.
TXG’s Financial PositionTXG exited the first quarter of 2026 with cash, cash equivalents and marketable securities of $539.8 million, up from $523.4 million at the end of the fourth quarter of 2025. Importantly, the company ended the quarter with no debt on its balance sheet, underscoring a solid solvency position.
TXG’s 2026 Guidance10x Genomics has maintained its revenue outlook for 2026.
10x Genomics expects 2026 revenues to be in the range of $600 million to $625 million. Excluding the non-recurring license and royalty revenue related to patent litigation settlements in 2026, this represents 0% to 4% growth over 2026.
Our Take10x Genomics exited the first quarter of 2026 with better-than-expected results, wherein both earnings and revenues beat the Zacks Consensus Estimate. While reported revenues declined year over year due to the absence of prior-year one-time license and royalty revenues, underlying business trends remained healthy, with Products and Services revenues rising on continued strength in consumables demand and higher services revenues. Growth across the EMEA and Asia-Pacific regions, expanding gross margin and disciplined cost controls were encouraging. The company also reported a significantly narrower operating loss year over year, supported by lower operating expenses and improving operating leverage.
During the quarter, 10x Genomics continued advancing its spatial biology and single-cell analysis portfolio through strategic innovation initiatives. The launch of Atera, its next-generation spatial whole-transcriptome platform designed to deliver single-cell sensitivity at unprecedented scale, marked a major technology milestone and is expected to support future growth following commercialization in the second half of 2026.
The company also partnered with Bioptimus to launch the STELA initiative, aimed at building foundational spatial datasets linking biology with disease outcomes using the Xenium platform, with planned expansion to Atera over time. Complementing these initiatives, TXG maintained a strong balance sheet with more than $539 million in cash and no debt, providing financial flexibility to support ongoing innovation and commercialization efforts.
TXG’s Zacks Rank and Stocks to ConsiderTXG currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space that are expected to report earnings soon are DexCom, Inc. (DXCM - Free Report) , Encompass Health Corporation (EHC - Free Report) and The Cooper Companies, Inc. (COO - Free Report) .
The Zacks Consensus Estimate for DexCom’s first-quarter 2026 adjusted earnings per share (EPS) is currently pegged at 47 cents. The consensus estimate for revenues is pegged at $1.18 billion. DXCM currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
DexCom has an estimated long-term growth rate of 20.6%. DXCM’s earnings yield of 4.1% compares favorably with the industry’s negative yield.
Encompass Health currently has a Zacks Rank #2. The Zacks Consensus Estimate for its first-quarter 2026 adjusted EPS is currently pegged at $1.51. The same for revenues is pegged at $1.57 billion.
Encompass Health has an estimated long-term growth rate of 8.8%. EHC’s earnings yield of 5.9% compares favorably with the industry’s 5.6%.
Cooper Companies currently carries a Zacks Rank #2. The Zacks Consensus Estimate for its second-quarter fiscal 2026 adjusted EPS is currently pegged at $1.10. The same for its revenues is pegged at $1.05 billion.
Cooper Companies has an estimated long-term growth rate of 8.4%. COO’s earnings yield of 7.2% compares favorably with the industry’s 6.1%.
IDEX Corporation $IEX Stock Position Cut by Weitz Investment Management Inc.Weitz Investment Management Inc. lessened its position in shares of IDEX Corporation (NYSE:IEX - Free Report) by 3.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 391,475 shares of the industrial products company's stock after selling 1
NYSE:IEX
Read IDEX Corporation $IEX Stock Position Cut by Weitz Investment Management Inc.
2 hours ago
Labcorp Holdings Inc. $LH Shares Sold by Weitz Investment Management Inc.MarketBeat
Weitz Investment Management Inc. trimmed its position in Labcorp Holdings Inc. (NYSE:LH - Free Report) by 28.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 99,750 shares of the medical research company's stock after s
NYSE:LH
Read Labcorp Holdings Inc. $LH Shares Sold by Weitz Investment Management Inc.
2 hours ago
Weitz Investment Management Inc. Trims Stake in Perimeter Solutions, SA $PRMMarketBeat
Weitz Investment Management Inc. reduced its stake in shares of Perimeter Solutions, SA (NYSE:PRM - Free Report) by 31.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 509,400 shares of the c
NYSE:PRM
Read Weitz Investment Management Inc. Trims Stake in Perimeter Solutions, SA $PRM
2 hours ago
Charter Communications, Inc. $CHTR Shares Sold by Weitz Investment Management Inc.MarketBeat
Weitz Investment Management Inc. cut its holdings in shares of Charter Communications, Inc. (NASDAQ:CHTR - Free Report) by 99.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 650 shares of the company's stock after selling 101
NASDAQ:CHTR
Read Charter Communications, Inc. $CHTR Shares Sold by Weitz Investment Management Inc.
2 hours ago
Weitz Investment Management Inc. Boosts Position in Roper Technologies, Inc. $ROPMarketBeat
Weitz Investment Management Inc. grew its holdings in Roper Technologies, Inc. (NASDAQ:ROP - Free Report) by 16.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 36,550 shares of the industrial products company's stock a
NASDAQ:ROP
Read Weitz Investment Management Inc. Boosts Position in Roper Technologies, Inc. $ROP
2 hours ago
Weitz Investment Management Inc. Has $36.02 Million Stock Position in Analog Devices, Inc. $ADIMarketBeat
Weitz Investment Management Inc. lessened its stake in shares of Analog Devices, Inc. (NASDAQ:ADI - Free Report) by 4.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 132,800 shares of the semicond
NASDAQ:ADI
Read Weitz Investment Management Inc. Has $36.02 Million Stock Position in Analog Devices, Inc. $ADI
On May 12, 2026, Quantedge Capital disclosed in a Securities and Exchange Commission (SEC) filing that it bought 212,600 shares of 10x Genomics (TXG 0.21%), an estimated $4.25 million transaction based on the quarterly average price.
What happenedAccording to a Securities and Exchange Commission (SEC) filing dated May 12, 2026, Quantedge Capital increased its stake in 10x Genomics by 212,600 shares. The estimated value of this purchase is $4.25 million, using the average closing price for the quarter. The position’s value at quarter-end increased by $5.52 million, reflecting both the share addition and changes in market price.
What else to knowThe resulting stake represents 4.84% of Quantedge’s 13F reportable AUM as of March 31, 2026.Top holdings after the filing:NYSE:PVH: $32.40 million (17.7% of AUM)NYSE:HLF: $28.29 million (15.5% of AUM)NYSE:BWA: $19.09 million (10.4% of AUM)NASDAQ:TXG: $8.84 million (3.8% of AUM)NYSE:ADNT: $7.91 million (4.3% of AUM)As of May 11, 2026, 10x Genomics shares were priced at $20.50, up 116% over the past year and vastly outperforming the S&P 500’s roughly 26% gain in the same period.Company overviewMetricValueMarket Capitalization$2.64 billionRevenue (TTM)$638.78 millionNet Income (TTM)($22.66 million)Price (as of market close May 11, 2026)$20.50Company snapshot10x Genomics offers instruments, consumables, and software for single cell analysis, spatial gene expression, and multiomic profiling, with primary revenue from sales of proprietary laboratory equipment and consumables.The firm operates a product-driven business model, generating recurring revenue through the sale of consumables used with installed instruments and ongoing software support.It targets academic institutions, government research labs, and biopharmaceutical and biotechnology companies engaged in advanced biological research.10x Genomics is a leading provider of advanced life science tools, enabling high-resolution analysis of biological systems at scale. The company leverages proprietary microfluidics and genomics technologies to support cutting-edge research in genomics and cellular biology. Its integrated platform and strong presence in research institutions position it as a key enabler in the rapidly evolving field of single-cell and spatial biology.
What this transaction means for investors10x Genomics’ recent performance hasn’t been perfect, but the latest earnings release gave investors some reasons to be bullish, and Quantedge appears to be positioning for growth tied to next-generation spatial biology and AI-driven drug discovery. While reported first-quarter revenue dipped 3% to $150.8 million, excluding one-time litigation revenue from last year, sales actually grew 9%. Gross margin improved to 70%, while operating expenses fell 15%, helping narrow the company’s operating loss substantially.
The bigger story may be product momentum. 10x recently launched Atera, which CEO Serge Saxonov called “the most significant product introduction” in company history. The platform is designed for spatial whole-transcriptome analysis at single-cell resolution, an area many researchers believe could become foundational for AI-powered biological modeling and precision medicine.
Now, it’ll matter whether 10x can execute on sustained commercial growth. The company still isn’t profitable, but with nearly $540 million in cash and marketable securities, it has the balance sheet to keep investing aggressively while competitors pull back.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends 10x Genomics. The Motley Fool recommends BorgWarner. The Motley Fool has a disclosure policy.
Serge Saxonov, Chief Executive Officer of 10x Genomics (TXG 0.21%), reported the direct sale of 28,893 shares of Common Stock in multiple open-market transactions between May 22 and May 26, 2026, with an aggregate transaction value of approximately $709,000, according to the SEC Form 4 filing.
Transaction summaryMetricValueShares sold (direct)28,893Transaction value~$709,000Post-transaction shares (direct)1,138,380Post-transaction value (direct ownership)~$27.93 millionTransaction and post-transaction values based on SEC Form 4 weighted average price ($24.54).
Key questionsHow does the size of this transaction compare to Serge Saxonov's prior selling activity?
This is the largest single open-market sale by Saxonov over the past two years, with the 28,893 shares sold exceeding the prior maximum of 16,152 shares and well above his historical average sale size of around 6,632 shares.What impact does this transaction have on Saxonov's overall ownership and future sale capacity?
The sale reduced his direct ownership to 1,138,380 shares; including indirect holdings through family trusts, his total position is 1,423,301 shares.Were any indirect holdings or derivative securities affected in this transaction?
No; all shares sold were held directly, with indirect holdings (totaling 284,921 shares via three trusts) unchanged and no derivative securities exercised or disposed.Does the transaction timing or structure signal a change in selling cadence, or is it explained by available capacity?
The larger sale size reflects a drawdown in available share capacity after a period of consistent smaller sales, rather than an escalation in disposition cadence; historical data show net selling over the past year, with total direct holdings declining by 26.86% since August 2024.Company overviewMetricValueMarket capitalization$3.59 billionRevenue (TTM)$638.78 millionNet income (TTM)($22.66 million)Company snapshot10x Genomics offers single cell and spatial genomics instruments, consumables, and software, including Chromium and Visium platforms, generating revenue from both hardware and recurring consumable sales.It operates a hybrid business model combining upfront equipment sales with a high-margin consumables and reagents stream, supported by proprietary microfluidics and bioinformatics solutions.The company serves academic research institutions, government labs, and biopharmaceutical and biotechnology companies globally, targeting organizations engaged in advanced biological and genetic research.10x Genomics is a leading life sciences technology company focused on enabling high-resolution analysis of biological systems through innovative single cell and spatial genomics solutions.
The company leverages a strong portfolio of proprietary technologies to drive adoption across research and clinical discovery markets. Its integrated platform and recurring consumables revenue position it as a key enabler of next-generation genomics research worldwide.
What this transaction means for investors10x Genomics CEO Serge Saxonov’s May 22 and May 26 sale of company stock is not a red flag for investors. The May 22 disposition involving 18,175 shares was executed to cover tax withholding obligations related to the vesting of restricted stock units.
As for the May 26 sale of 10,718 shares, it was implemented as part of a Rule 10b5-1 trading plan, adopted in November of 2025. Such pre-arranged trading plans are often implemented by insiders to avoid accusations of making trades based on insider information.
The May 26 transaction occurred at a time when 10x Genomics shares were soaring. They eventually hit a 52-week high of $28.86 on May 29, just days after Saxonov’s disposition. Still, he retained over one million directly-held shares after the transaction, indicating that his stake in the company remains plentiful.
Although 10x Genomics revenue in the first quarter fell 3% year over year to $150.8 million, the company’s stock is up because it managed costs well, reducing its Q1 net loss to $13.5 million compared to a loss of $34.4 million in the prior year.
Robert Izquierdo has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends 10x Genomics. The Motley Fool has a disclosure policy.
Acquisition Expands 10x Genomics' Capabilities in Proteomics
, /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced the acquisition of Proteintech Genomics, a division within Proteintech Group, a company specializing in developing high-plex proteomic solutions for single cell and spatial applications on 10x platforms.
The acquisition marks a strategic expansion of 10x's proteomics capabilities. Proteintech Genomics brings differentiated technologies, including its Human Discovery Panel, the largest antibody-based single cell protein panel, designed to support integrated analysis of intracellular proteins, cell surface proteins and transcriptomic profiles within sequencing-compatible workflows. The Human Discovery Panel is compatible with Flex chemistry, including the Flex Apex assay.
"We believe the future of biological analysis will increasingly integrate transcriptomic and proteomic information at the single cell and spatial levels," said Michael Schnall-Levin, Chief Technology Officer, Chief Strategy Officer and Founding Scientist of 10x Genomics. "The acquisition of Proteintech Genomics expands our capabilities in proteomics and supports our broader vision for richer multiomic approaches to understanding biology."
The acquisition builds on 10x's broader vision to enable multimodal biological analysis across the company's single cell and spatial platforms, including protein capabilities planned for the recently launched Atera platform.
Researchers increasingly combine transcriptomic and proteomic-based measurements to gain complementary insights into cellular identity, state and function. These approaches have helped advance discovery across immunology, oncology, neuroscience and broader cell biology research. Today, researchers often rely on multiple vendors and workflows to harmonize RNA and protein analysis in single cell experiments.
"From day one, Proteintech Genomics was built around the belief that RNA and protein measurements are most powerful when used together. Because our technologies were designed to integrate with 10x workflows, joining the 10x team feels like a natural next chapter. We are excited about the opportunity to accelerate innovation together and expand access to integrated multiomic approaches for researchers around the world," said Dr. Kristopher Nazor, CEO of Proteintech Genomics. "Single cell and spatial biology has always promised a more complete picture of cellular state - protein and RNA together, at scale, across tissues. We're finally in a position to deliver on that promise."
Proteintech Genomics' protein panels were purpose-built for 10x single cell workflows and are already used by many researchers to simultaneously analyze RNA and protein. The acquisition brings together 10x's expertise in scalable single cell and spatial biology platforms with Proteintech Genomics' advanced capabilities in protein detection.
"Biology is bigger than transcriptomics alone. Bringing scalable protein measurements into single cell and spatial biology is an important step toward richer, more predictive views of cellular state — and ultimately, virtual cell models that better reflect the complexity of living systems," said Ci Chu, Senior Vice President, AI-Enabled Discovery, Xaira Therapeutics.
For more than a decade, 10x has pioneered technologies that have transformed how scientists measure and understand biology. The acquisition of Proteintech Genomics continues that legacy, expanding the company's multiomic capabilities and reinforcing its commitment to developing breakthrough technologies that accelerate the mastery of biology and advance human health.
The terms of the transaction were not disclosed. 10x Genomics believes the transaction will not meaningfully impact its near-term financial outlook.
About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X, Facebook, Bluesky or YouTube.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements included in this press release, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "see," "estimate," "predict," "potential," "would," "likely," "seek" or "continue" or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics, Inc.'s acquisition of Proteintech Genomics, Inc., integration activities, potential commercial reach, potential impacts of its products and services and potential products, applications and capabilities and financial outlook. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management. Actual outcomes and results could differ materially from these statements due to a number of factors and such statements should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release. 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in 10x Genomics' expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. The material risks and uncertainties that could affect 10x Genomics, Inc.'s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's most recently-filed 10-Q and 10-K and elsewhere in the documents 10x Genomics, Inc. files with the Securities and Exchange Commission from time to time.
Disclosure Information
10x Genomics uses filings with the Securities and Exchange Commission, its website (https://www.10xgenomics.com/), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
Key Takeaways 10x Genomics acquires Proteintech Genomics to expand proteomics and multiomics capabilities.TXG gains 4.8% after the deal, which adds protein-analysis tools compatible with Flex workflows.Proteintech technologies support combined RNA and protein analysis across single-cell platforms. 10x Genomics (TXG - Free Report) recently announced the acquisition of Proteintech Genomics, a division within Proteintech Group that develops high-plex proteomic solutions for single-cell and spatial biology applications. The move expands TXG's capabilities in proteomics and supports its broader strategy of advancing multiomics research through integrated RNA and protein analysis.
Proteintech Genomics brings technologies, including the Human Discovery Panel, an antibody-based single-cell protein panel compatible with 10x Genomics' Flex chemistry workflows. Management believes the acquisition will strengthen its single-cell and spatial biology platforms, while the company expects the transaction to have no meaningful impact on its near-term financial outlook.
Likely Trend of TXG Stock Following the NewsShares of TXG have gained 4.8% since the announcement in yesterday’s trading. In the year-to-date period, shares of the company have gained 87.6% against the industry’s 20.5% decline. The S&P 500 increased 8.4% in the same time frame.
The acquisition is expected to strengthen TXG's long-term growth prospects by expanding its presence in the rapidly evolving proteomics market and enhancing its multiomics capabilities. By integrating Proteintech Genomics' protein-analysis technologies with its existing single-cell and spatial platforms, TXG can offer researchers a more comprehensive view of cellular biology through combined RNA and protein measurements. The deal also has the potential to increase customer adoption, drive higher consumables usage and improve platform stickiness, while positioning the company to capitalize on emerging opportunities in AI-driven biological modeling and next-generation life sciences research.
TXG currently has a market capitalization of $3.7 billion.
Image Source: Zacks Investment Research
More on the NewsThe acquisition significantly broadens 10x Genomics' proteomics portfolio by adding Proteintech Genomics' differentiated technologies, including the Human Discovery Panel, which the company describes as the largest antibody-based single-cell protein panel.
The panel is designed to support integrated analysis of intracellular proteins, cell-surface proteins and transcriptomic profiles within sequencing-compatible workflows. Importantly, the technology is already compatible with 10x Genomics' Flex chemistry, including the Flex Apex assay, enabling researchers to combine RNA and protein measurements within a unified workflow. Management believes that integrating transcriptomic and proteomic information at the single-cell and spatial levels will play an increasingly important role in advancing biological research and discovery.
The transaction also aligns with 10x Genomics' broader strategy of enabling multimodal biological analysis across its single-cell and spatial platforms. Proteintech Genomics' protein panels were purpose-built for 10x workflows and are already being used by researchers to simultaneously analyze RNA and protein expression. By bringing these capabilities in-house, TXG aims to simplify workflows that currently require multiple vendors and technologies to harmonize RNA and protein data.
The company also sees opportunities to extend these protein-analysis capabilities to its recently launched Atera platform. Researchers across fields such as immunology, oncology, neuroscience and cell biology are increasingly adopting combined transcriptomic and proteomic approaches to gain deeper insights into cellular identity, function and disease mechanisms, making the acquisition a strategic addition to TXG's long-term innovation roadmap.
Favorable Industry Prospect for TXGPer a report by Grand View Research, the global proteomics market size was valued at $38.4 billion in 2025 and is projected to grow beyond $97.7 billion by 2033, at a CAGR of 13.3%.
The market is witnessing significant growth driven by the rising prevalence of chronic and infectious diseases, growing preference for personalized medicine and the increasing demand for rapid & advanced diagnostic solutions in target disease treatment.
Recent Developments by TXGRecently, 10x Genomics exited the first quarter of 2026 on a solid note, with both earnings and revenues surpassing the Zacks Consensus Estimate. While total revenues declined year over year due to the absence of prior-year one-time license and royalty revenues, underlying business performance remained healthy, driven by higher consumables demand, increased services revenues, growth across the EMEA and Asia-Pacific regions, expanding gross margin and disciplined cost management.
The company also significantly narrowed its operating loss year over year. During the quarter, TXG strengthened its innovation pipeline with the launch of Atera, a next-generation spatial whole-transcriptome platform that offers single-cell sensitivity at scale and is expected to support growth following its planned commercialization in the second half of 2026.
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , West Pharmaceutical (WST - Free Report) and Intuitive Surgical (ISRG - Free Report) .
Globus Medical, currently flaunting a Zacks Rank #1 (Strong Buy), reported a first-quarter 2026 adjusted earnings per share (EPS) of $1.12 per share, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 10.2% compared with the industry’s 12.6% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.
West Pharmaceutical, currently sporting a Zacks Rank #1, reported first-quarter 2026 EPS of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%.
WST has an estimated long-term earnings growth rate of 13.9% compared with the industry’s 9.5% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.
Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.
ISRG has a long-term estimated growth rate of 14.6% compared with the industry’s 12.6% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
